The effect of probiotic fermented milk that includes Bifidobacterium lactis CNCM I-2494 on the reduction of gastrointestinal discomfort and symptoms in adults: a narrative review
Carregando...
Citações na Scopus
13
Tipo de produção
article
Data de publicação
2015
Editora
AULA MEDICA EDICIONES
Indexadores
Título da Revista
ISSN da Revista
Título do Volume
Autores
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
NUTRICION HOSPITALARIA, v.32, n.2, p.501-509, 2015
Resumo
Aim: determine the effectiveness of fermented milk that included Bifidobacterium lactis CNCM I-2429 for reducing gastrointestinal (GI) discomfort in healthy adults. Methods: we conducted a systematic literature search to identify studies reporting the use of B. animalis spp. lactis for GI discomfort/comfort in healthy adults. A total of 5329 records were identified, of these 99 full-text articles were assessed. Searches for additional trials were conducted using the names of authors of each identified study and several relevant databases. The study selection was carried out according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Studies were included if they were randomized controlled trials; the included subjects were healthy adults; and the intervention group received B. lactis CNCM I-2494. Studies were excluded if they were non-randomized trials, if they included adults who were not healthy, if they included the use of any other intervention, or if they compared different products without a placebo group. The methodological quality of the studies was evaluated using the Oxford Quality Scale and the Cochrane Concealment Assessment. A meta-analysis was not possible. Results: the search strategy identified two studies that included a total of 538 healthy women, aged 18-60 years, normal weight or overweight (BMI 18-30 kg/m(2)). GI well-being was significantly improved in the Probiotic group vs. the Control group in one study, with no differences in the other. The percentage of responders for GI well-being was higher in the Probiotic group vs. the Control group in the first study but not in the second. GI symptoms were significantly decreased in the Probiotic group vs. the Control group in both studies. Bowel function was assessed by one study; the stool frequency did not differ between the groups, but a decrease in stool consistency was observed in the Probiotic group but not in the Control group. Possible mechanisms of action (gut motility, hypersensitivity, gut permeability, and gut microbiota) were also described. Conclusion: probiotic fermented milk containing B. lactis CNCM I-2494 by healthy women may improve GI well-being and decrease the frequency of GI symptoms.
Palavras-chave
Probiotic, Gastrointestinal discomfort, Healthy subjects, Women
Referências
- Agostini S, 2012, NEUROGASTROENT MOTIL, V24, DOI 10.1111/j.1365-2982.2011.01865.x
- Agrawal A, 2009, ALIMENT PHARM THER, V29, P104, DOI 10.1111/j.1365-2036.2008.03853.x
- Azpiroz F, 2014, J CLIN GASTROENTEROL
- Bouvier M., 2001, Bioscience and Microflora, V20, P43
- Costilla VC, 2014, CLIN GERIATR MED, V30, P107, DOI 10.1016/j.cger.2013.10.001
- Dash S, 2015, CURR OPIN PSYCHIATR, V28, P1, DOI 10.1097/YCO.0000000000000117
- Ford AC, 2014, AM J GASTROENTEROL, V109, P1547, DOI 10.1038/ajg.2014.202
- Ford AC, 2014, AM J GASTROENTEROL, V109, P1546, DOI 10.1038/AJG.2014.202
- Ford AC, 2014, AM J GASTROENTEROL, V109, P1562, DOI 10.1038/AJG.2014.202
- Guyonnet D, 2009, J DIG DIS, V10, P61, DOI 10.1111/j.1751-2980.2008.00366.x
- Guyonnet D, 2009, BRIT J NUTR, V102, P1654, DOI 10.1017/S0007114509990882
- Guyonnet D, 2013, BRIT J NUTR, V110, P1263, DOI 10.1017/S0007114513000275
- Higgins JP, 2011, BMJ-BRIT MED J, V18, P343, DOI 10.1136/BMJ.D5928
- Hyland NP, 2014, WORLD J GASTROENTERO, V20, P8859, DOI 10.3748/wjg.v20.i27.8859
- Iovino P, 2014, WORLD J GASTROENTERO, V20, P14407, DOI 10.3748/wjg.v20.i39.14407
- Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4
- Marteau P, 2013, NEUROGASTROENT MOTIL, V25, DOI 10.1111/nmo.12078
- Marteau P, 2002, ALIMENT PHARM THERAP, V16, P587, DOI 10.1046/j.1365-2036.2002.01188.x
- Mayer EA, 2014, J NEUROSCI, V34, P15490, DOI 10.1523/JNEUROSCI.3299-14.2014
- McNulty NP, 2011, SCI TRANSL MED, V3, DOI 10.1126/SCITRANSLMED.3002701
- Medina M, 2007, CLIN EXP IMMUNOL, V150, P531, DOI 10.1111/j.1365-2249.2007.03522.x
- Menees SB, 2012, AM J GASTROENTEROL, V107, P28, DOI 10.1038/ajg.2011.355
- Metchnikoff E, 1908, OPTIMISTIC STUDIES
- Miller LE, 2013, WORLD J GASTROENTERO, V19, P4718, DOI 10.3748/wjg.v19.i29.4718
- Moayyedi P, 2010, GUT, V59, P325, DOI 10.1136/gut.2008.167270
- Moayyedi P, 2014, AM J GASTROENTEROL, V109, P1367, DOI 10.1038/ajg.2014.195
- Moher D, 2009, PLOS MED, V21, P6, DOI 10.1371/J0URNAL.PMED.1000097
- Rijkers GT, 2010, J NUTR, V140, P671, DOI 10.3945/JN.109.113779
- Sanders Mary Ellen, 2011, Gut Microbes, V2, P127, DOI 10.4161/gmic.2.3.16174
- SANDERS ME, 2008, CLIN INFECT DIS S2, V46, pS58, DOI 10.1086/523341
- Sanders ME, 2013, GUT, V62, P787, DOI 10.1136/gutjnl-2012-302504
- Sanders ME, 2008, CLIN INFECT DIS S2, V46, pS144, DOI [10.1086/523341, DOI 10.1086/523341]
- Sanders ME, 2009, FUNCTIONAL FOOD REV, V1, P3
- Simren M, 2013, GUT, V62, P159, DOI 10.1136/gutjnl-2012-302167
- Tillisch K, 2013, GASTROENTEROLOGY, V144, P1394, DOI 10.1053/j.gastro.2013.02.043
- Tojo R, 2014, WORLD J GASTROENTERO, V20, P15163, DOI 10.3748/wjg.v20.i41.15163
- van Kerkhoven LAS, 2008, NETH J MED, V66, P18
- Veiga P, 2010, P NATL ACAD SCI USA, V107, P18132, DOI 10.1073/pnas.1011737107
- Veiga P, 2014, SCI REP, V4, P1, DOI 10.1038/SREP06328